全文获取类型
收费全文 | 3638篇 |
免费 | 165篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 88篇 |
妇产科学 | 60篇 |
基础医学 | 291篇 |
口腔科学 | 62篇 |
临床医学 | 316篇 |
内科学 | 333篇 |
皮肤病学 | 60篇 |
神经病学 | 391篇 |
特种医学 | 180篇 |
外科学 | 615篇 |
综合类 | 417篇 |
预防医学 | 312篇 |
眼科学 | 29篇 |
药学 | 467篇 |
1篇 | |
中国医学 | 87篇 |
肿瘤学 | 118篇 |
出版年
2023年 | 56篇 |
2022年 | 148篇 |
2021年 | 155篇 |
2020年 | 127篇 |
2019年 | 153篇 |
2018年 | 151篇 |
2017年 | 111篇 |
2016年 | 111篇 |
2015年 | 120篇 |
2014年 | 200篇 |
2013年 | 220篇 |
2012年 | 178篇 |
2011年 | 192篇 |
2010年 | 164篇 |
2009年 | 181篇 |
2008年 | 180篇 |
2007年 | 141篇 |
2006年 | 135篇 |
2005年 | 119篇 |
2004年 | 115篇 |
2003年 | 107篇 |
2002年 | 75篇 |
2001年 | 63篇 |
2000年 | 49篇 |
1999年 | 53篇 |
1998年 | 55篇 |
1997年 | 33篇 |
1996年 | 56篇 |
1995年 | 30篇 |
1994年 | 38篇 |
1993年 | 29篇 |
1992年 | 28篇 |
1991年 | 30篇 |
1990年 | 23篇 |
1989年 | 23篇 |
1988年 | 13篇 |
1987年 | 11篇 |
1986年 | 15篇 |
1985年 | 23篇 |
1984年 | 25篇 |
1983年 | 9篇 |
1982年 | 16篇 |
1981年 | 14篇 |
1980年 | 17篇 |
1979年 | 10篇 |
1978年 | 9篇 |
1977年 | 7篇 |
1976年 | 9篇 |
1973年 | 7篇 |
1972年 | 6篇 |
排序方式: 共有3863条查询结果,搜索用时 15 毫秒
121.
122.
123.
Yash Paul Sharma Krishna Santosh Vemuri Dinakar Bootla Kewal Kanabar C.R. Pruthvi Navjyot Kaur Krishna Prasad Nevali Prashant Panda G. Kasinadhuni Lipi Uppal Soumitra Mohanty 《Indian heart journal》2021,73(2):174-179
BackgroundCardiovascular disease is the leading cause of death in India. Our aim is to study the clinical, epidemiological profile and in-hospital outcomes of patients presenting with acute coronary syndrome.MethodsWe did a prospective single center observational study of the 1203 patients presenting with ACS to a tertiary referral center in North India over a period of one year (July 2018–June 2019).ResultsThe mean age of study population was 58.4 ± 12.5 years. STEMI and NSTE-ACS accounted for 69.9% and 31.1% respectively. 62.1% of our patients were from rural background. The median time to hospital admission was 600 min for STEMI patients, thrombolysis was performed in 52% of cases. Cardiogenic shock at presentation was noted in 18%. Coronary angiography and percutaneous coronary intervention were done in 1062 (88.3%) and 733 (60.9%) patients respectively. The overall in-hospital mortality was 7.6%. STEMI patients had higher mortality than NSTE-ACS (8.9% vs 4.5% p < 0.001). Female gender (OR?3.306 C.I. 1.87–5.845), severe MR (OR?4.65, C.I.?1.187–18.18), acute kidney injury (AKI) at admission (OR-5.15, C.I.?2.5–10.63), higher Killip class (class III/IV) (OR?3.378,C.I.?1.292–8.849), AF (OR?3.25, C.I.?1,18–8.92), complete heart block (CHB) (OR?4.44,C.I.?2.09–9.43) and right bundle branch block (RBBB) (OR?2.86, C.I.?1.2–6.8) were significant predictors of in hospital mortality.ConclusionsOur study represents the predominance of STEMI as the initial ACS presentation with a considerable delay in first medical contact and higher prevalence of cardiogenic shock (CS). STEMI patients had higher mortality. Female sex, severe MR, AKI, higher Killips class, AF, CHB, RBBB being predictors of high in-hospital mortality in ACS patients. 相似文献
124.
Bang LE Ripa RS Grande P Kastrup J Clemmensen PM Wagner GS 《Journal of electrocardiology》2008,41(6):609-613
Introduction
Magnetic resonance imaging using the delayed contrast-enhanced (DE-MRI) method can be used for characterizing and quantifying myocardial infarction (MI). Electrocardiogram (ECG) score after the acute phase of MI can be used to estimate the portion of left ventricular myocardium that has infracted. There are no comparison of serial changes on ECG and DE-MRI measuring infarct size.Aim
The general aim of this study was to describe the acute, healing, and chronic phases of the changes in infarct size estimated by the ECG and DE-MRI. The specific aim was to compare estimates of the Selvester QRS scoring system and DE-MRI to identify the difference between the extent of left ventricle occupied by infarction in the acute and chronic phases.Methods
In 31 patients (26 men, age 56 ± 9) with reperfused ST-elevation MI (11 anterior, 20 inferior), standard 12-lead ECG and DE-MRI were taken from 1 to 2 days (acute), 1 month (healing), and 6 months (chronic) after the MI. Selvester QRS scoring was used to estimate the infarct size from the ECG.Results
The correlation values between infarct size measured by DE-MRI and QRS scoring range from 0.33 to 0.43 higher for anterior than inferior infarcts. The infarct size estimated by QRS scoring was larger (about 5% of the left ventricle) than infarct size by DE-MRI acute and 1 month, but at 6 months, there was no difference. In about half of the patients, the QRS score agreed with DE-MRI in change of infarct size from acute to 6 months.Conclusion
In conclusion, the Selvester QRS scoring system is in half of the patients with reperfused first time MI in good accordance with DE-MRI in identifying a decrease or no change in the extent of left ventricle occupied by infarction in the acute and chronic phases. 相似文献125.
126.
《Vaccine》2015,33(24):2813-2822
BackgroundIn the first five I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) influenza seasons vaccine effectiveness (VE) results were relatively homogenous among participating study sites. In 2013–2014, we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in six European Union (EU) countries to measure 2013–2014 influenza VE against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Influenza A(H3N2) and A(H1N1)pdm09 viruses co-circulated during the season.MethodsPractitioners systematically selected ILI patients to swab within eight days of symptom onset.We compared cases (ILI positive to influenza A(H3N2) or A(H1N1)pdm09) to influenza negative patients. We calculated VE for the two influenza A subtypes and adjusted for potential confounders. We calculated heterogeneity between sites using the I2 index and Cochrane's Q test. If the I2 was <50%, we estimated pooled VE as (1 minus the OR) × 100 using a one-stage model with study site as a fixed effect. If the I2 was >49% we used a two-stage random effects model.ResultsWe included in the A(H1N1)pdm09 analysis 531 cases and 1712 controls and in the A(H3N2) analysis 623 cases and 1920 controls. For A(H1N1)pdm09, the Q test (p = 0.695) and the I2 index (0%) suggested no heterogeneity of adjusted VE between study sites. Using a one-stage model, the overall pooled adjusted VE against influenza A(H1N1)pdm2009 was 47.5% (95% CI: 16.4–67.0).For A(H3N2), the I2 was 51.5% (p = 0.067). Using a two-stage model for the pooled analysis, the adjusted VE against A(H3N2) was 29.7 (95% CI: −34.4–63.2).ConclusionsThe results suggest a moderate 2013–2014 influenza VE against A(H1N1)pdm09 and a low VE against A(H3N2). The A(H3N2) estimates were heterogeneous among study sites. Larger sample sizes by study site are needed to prevent statistical heterogeneity, decrease variability and allow for two-stage pooled VE for all subgroup analyses. 相似文献
127.
Mycotoxins are secondary metabolites produced by fungi contaminating the food chain that are toxic to animals and humans. Children up to 12 years old are recognized as a potentially vulnerable subgroup with respect to consumption of these contaminants. Apart from having a higher exposure per kg body weight, they have a different physiology from that of adults. Therefore they may be more sensitive to neurotoxic, endocrine and immunological effects. For these reasons, a specific and up-to-date risk analysis for this category is of great interest.In this review, an accurate analysis of the main mycotoxins occurring in food intended for children (deoxynivalenol, aflatoxins, ochratoxins, patulin and fumonisins) is presented. In particular, known mechanisms of toxicity and levels of exposure and bioaccessibility in children are shown. In addition, recent discoveries about the strategies of mycotoxins managing are discussed. 相似文献
128.
《Value in health》2015,18(4):484-492
ObjectiveTo compare prices of medicines, both originators and generics, in New Zealand and 16 European countries.MethodsEx-factory price data as of December 2012 from New Zealand and 16 European countries were compared for a basket of 14 medicines, most of which were at least partially funded by the state in the 17 countries. Five medicines had, at least in some countries, generic versions on the market whose prices were also analyzed. Medicine price data for the 16 European countries were provided by the Pharma Price Information service. New Zealand medicine prices were retrieved from the New Zealand Pharmaceutical Schedule. Unit prices converted into euro were compared at the ex-factory price level.ResultsFor the 14 medicines surveyed, considerable price differences at the ex-factory price level were identified. Within the European countries, prices in Greece, Portugal, the United Kingdom, and Spain ranked at the lower end, whereas prices in Switzerland, Germany, Denmark, and Sweden were at the upper end. The results for New Zealand compared with Europe were variable. New Zealand prices were found in the lowest quartile for five medicines and in the highest quartile for seven other products. Price differences between the originator products and generic versions ranged from 0% to 90% depending on the medicine and the country.ConclusionsMedicine prices varied considerably between European countries and New Zealand as well as among the European countries. These differences are likely to result from national pricing and reimbursement policies. 相似文献
129.
J. L. Buttriss 《Nutrition Bulletin》2015,40(3):211-222
The European Nutrition and Health Claims Regulation ensures that any claims on European Union food labels are substantiated by robust scientific evidence; is this promoting innovation in the food industry and enabling consumers to make meaningful food choices? This paper provides an overview of the Regulation and some of the issues that have arisen since its implementation in 2007, with examples. It also discusses several European Commission‐funded projects that are underway, in particular BACCHUS (FP7/2007–2013; 312090: www.bacchus‐fp7.eu ) that is providing support to small‐ and medium‐sized enterprises that are considering whether to use or apply for health claims. 相似文献
130.
Sutton AJ Hope VD Mathei C Mravcik V Sebakova H Vallejo F Suligoi B Brugal MT Ncube F Wiessing L Kretzschmar M 《Journal of viral hepatitis》2008,15(11):809-816
A number of studies have been conducted in injecting drug user (IDU) populations in Europe, in which the prevalence of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) was measured together with demographic and epidemiological information such as age and the age at first injection. A measure of the risk of becoming infected is the force of infection (FOI), defined as the per capita rate at which susceptible individuals acquire infection. The objective of this study was to estimate the FOI and its heterogeneity for HBV, HCV and HIV (where available) for IDU populations in a number of countries in Europe. Data were obtained from five countries: Belgium, the United Kingdom, Spain and Italy, and the Czech Republic, which provided two data sets. The model describes the prevalence of infection as a function of the FOI that may vary over time or duration of IDU. In addition to this, if two or more infections were being considered then a parameter describing the potential heterogeneity of the FOI within the IDU population was also estimated. The results here add to the growing evidence that new initiates to injecting are at an increased risk of blood-borne viral infection compared with more experienced IDUs. In addition, there is evidence of individual heterogeneity of FOI estimates within the overall IDU populations. This suggests that different proportions of individuals in each population are at increased risk of infection compared with the rest of the population. Future interventions should identify and target these individuals. Moreover, changes over time in individual heterogeneity estimates of IDU populations may provide an indicator for measuring intervention impacts. 相似文献